Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials

Autor:	Eva Natukunda, Sean E Collins, Susan K. Chuck, Diana M. Brainard, Faiza Ajana, Hui Wang, Kirsten White, Chloe Orkin, Cheryl A. Pikora, Cissy Kityo, Tariro Makadzange, Ya-Pei Liu, Bhumi Gandhi-Patel, Xuelian Wei, Ian R. McNicholl, Ellen Koenig
Jazyk:	angličtina
Rok vydání:	2021
Předmět:	Adult medicine.medical_specialty Adolescent Anti-HIV Agents Pyridones Population Human immunodeficiency virus (HIV) Renal function HIV Infections Emtricitabine medicine.disease_cause Tenofovir alafenamide Gastroenterology Heterocyclic Compounds 4 or More Rings Piperazines Young Adult Internal medicine medicine Humans Pharmacology (medical) education Child Tenofovir Aged education.field_of_study Emtricitabine tenofovir alafenamide Alanine Bictegravir bictegravir business.industry Adenine HIV Clinical Science Middle Aged Amides Regimen Drug Combinations Infectious Diseases female Treatment Outcome HIV-1 business Heterocyclic Compounds 3-Ring medicine.drug
Zdroj:	Journal of Acquired Immune Deficiency Syndromes (1999)
ISSN:	1944-7884 1525-4135
Popis:	Background: We characterized the efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in a broad population of pediatric/adolescent/adult/elderly females living with HIV (FWH). Setting: Integrated analysis. Methods: Available data from 5 trials were integrated. Week 48 virologic suppression (HIV-1 RNA
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c1c9770face3dd8231e537eb4f93f45 http://europepmc.org/articles/PMC8547745 Zobrazit plný text záznamu